Friday, December 15, 2017 2:23:28 PM
I think we see teens in Feb. April should provide the first Q with a real profit. By then the accounting depreciation and amortization numbers fall off the P&L. Even without RMAT, partnership, or an outright buyout, I believe we will see a quarter by the second week of April.
I hope to see real progress with the FDA before that time. Realistically, there are 4 different classifications of RMAT including fast track or even phase 4 approval. Fast track would likely still require a partnership, but USRM could realistically use the information they have already attained to gain phase 4. RMAT allows clinical as well as non-clinical data to be used to gain approval. Should they get phase 4 approval, USRM would be a buyout candidate at substantially higher prices.
Even if RMAT doesn't happen at all, we have Right to Try laws that provide a work around. Revenues for the K should be very nice. Also, additional clinics should be announced.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM